Earnings Feed
Start Free
NEUROCRINE BIOSCIENCES INC·4

Feb 17, 5:45 PM ET

Delaet Ingrid 4

Research Summary

AI-generated summary

Updated

Neurocrine (NBIX) Chief Regulatory Officer Ingrid Delaet Receives Award

What Happened
Ingrid Delaet, Chief Regulatory Officer of Neurocrine Biosciences (NBIX), had multiple restricted stock units (RSUs) and performance RSUs (PRSUs) vest on Feb 12–13, 2026. The filing shows conversion/award transactions that resulted in the acquisition of a total of 61,008 shares (various "M" and "A" entries at $0.00) and the withholding of 13,126 shares to satisfy tax obligations ("F" entries). The withheld shares were valued at a combined $1,628,301 (withholdings priced at $123.10 and $124.12). No open‑market sale was reported — shares were withheld solely for taxes.

Key Details

  • Transaction dates: Feb 12–13, 2026; filing date: Feb 17, 2026.
  • Transaction codes: M = exercise/conversion of derivative; A = grant/award (vesting); F = shares withheld to satisfy tax withholding.
  • Acquired (vested/converted): 61,008 shares (aggregate from multiple RSU/PRSU vesting/conversion lines, $0 exercise price).
  • Shares withheld for taxes (disposed): 13,126 shares, totaling $1,628,301 (881 @ $123.10; remaining withholdings @ $124.12).
  • Net increase in shares held (acquired minus withheld): 47,882 shares.
  • Notable footnotes:
    • F1: Shares were withheld by the company to satisfy tax withholding — no shares were sold on the open market.
    • F2: PRSUs granted May 19, 2023 vested at 125% of target after certification on Feb 13, 2026, driving a large payout.
    • F4–F6: Several RSU grants had scheduled vesting on Feb 12–13, 2026 (1,600; 1,401; 1,359 shares respectively).
  • Shares owned after the transactions are not listed in the provided filing excerpt.
  • Timeliness: Filing was submitted Feb 17 for Feb 12–13 transactions — this is beyond the typical 2-business-day Section 16 reporting window and may be late.

Context
These entries reflect routine equity compensation vesting and tax-withholding (not open-market selling). For derivative-related entries, the filing shows conversion/vesting of RSUs/PRSUs (M/A) and the company withholding shares (F) to cover tax liabilities — effectively a cashless/tax-satisfying action, not a market sell that signals liquidity or investment intent.